Key Highlights
- Rocket Pharmaceuticals received FDA accelerated approval for KRESLADI, a groundbreaking gene therapy designed to treat severe leukocyte adhesion deficiency-I (LAD-I) in pediatric patients.
- Shares of RCKT surged by as much as 9% during premarket hours on Friday, later stabilizing at approximately 6% gains.
- This marks the first FDA-sanctioned gene therapy specifically targeting severe LAD-I, a rare immune disorder that can be fatal in children.
- Rocket received a Rare Pediatric Disease Priority Review Voucher from the FDA, which the biotech firm intends to sell for additional revenue.
- The green light follows a previous rejection in June 2024, after which Rocket provided supplementary data requested by regulators.
Rocket Pharmaceuticals saw its stock price climb as high as 9% in Friday’s premarket session after the FDA authorized KRESLADI, eventually stabilizing around 6% higher at market open.
Rocket Pharmaceuticals, Inc., RCKT
The regulatory clearance was granted through the accelerated pathway, which relies on preliminary clinical evidence—in this case, elevated neutrophil CD18 and CD11a surface expression levels. Complete verification of therapeutic benefit will require extended follow-up data from a currently active clinical trial and a post-approval monitoring registry.
KRESLADI, scientifically designated as marnetegragene autotemce, represents an autologous hematopoietic stem cell-based gene therapy. Its approved indication covers pediatric patients diagnosed with severe LAD-I resulting from biallelic ITGB2 gene variants who lack access to an HLA-matched sibling donor for conventional stem cell transplantation.
LAD-I represents an exceptionally rare inherited immunodeficiency disorder. The condition triggers repeated infections and demonstrates elevated mortality rates in early childhood when left untreated. Within the United States, occurrence is approximated at one case per 100,000 to 200,000 live births, with severe presentations accounting for roughly two-thirds of all diagnoses.
KRESLADI now stands as the inaugural FDA-sanctioned gene therapy addressing this medical condition.
The path to approval encountered significant obstacles. Regulatory authorities initially declined the biologics license application in June 2024, requesting that Rocket furnish additional supporting data before final evaluation could proceed.
Rocket subsequently resubmitted the BLA, which the FDA accepted in October 2024, establishing March 28, 2026 as the projected decision deadline—a timeline the agency successfully honored.
Priority Review Voucher Provides Additional Revenue Opportunity
Accompanying the approval, the FDA bestowed upon Rocket a Rare Pediatric Disease Priority Review Voucher. These instruments can be transferred to other pharmaceutical manufacturers for sums reaching hundreds of millions of dollars and represent a substantial financial incentive beyond the approval itself.
Rocket announced its intention to assess opportunities for converting the voucher into capital to strengthen its financial position.
“The approval of KRESLADI represents an important milestone for the severe LAD-I community,” said CEO Gaurav Shah.
Scientific Foundation and Development
The research underpinning KRESLADI’s creation received partial financing from the California Institute for Regenerative Medicine. The therapeutic agent addresses dysfunction in the ITGB2 gene, which produces a critical protein enabling white blood cells to combat infectious agents.
The Cranbury, New Jersey-headquartered biotechnology company has pursued this regulatory milestone over multiple years.
The FDA established March 28, 2026 as the decision deadline for the resubmitted BLA, and regulators delivered approval precisely on the scheduled date.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
